We need a streamlined approach where stakeholders can perform critical tasks — from enrollment and patient consent to prior authorization

Briana Contreras, an editor with Managed Healthcare Executive, and Peter Wehrwein, managing editor of MHE, got to chatting with the...

The Academy of Managed Care Pharmacy is throwing its support behind federal legislation that would create a Medicare benefit category for...

Jeffrey Casberg, Senior Director of Pharmacy at IPD Analytics discusses some of the high-impact specialty drugs in various therapeutic...

Specialty drugs are expected to comprise 80% of the FDA approvals this year. Among them are gene therapies for hemophilia A and Duchenne...

Dr. Billings, PharmD, BCGP, and Dr. Mahler, PhD, of IPD Analytics discuss specialized treatment with Beta Thalassemia at AMCP 2023. By...

A deep dive into the relationships between manufacturers of specialty drugs and the pharmacies they choose for their limited and...

PARPi monotherapy has been a milestone in the management of many BRCA1/2-mutated cancers, offering patients and prescribers the hope of...

Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic,...

Julie Kendle, Director, Clinical Pharmacy Director, Clinical Pharmacy at IPD Analytics addresses tips on improving accumulators and ways...

The FDA approved the first high-concentration adalimumab biosimilar. A low-concentration version of the biosimilar, Hadlima, was already...

The budget allocates half of the money for the development of low-cost interchangeable insulin biosimilars and the other half for...

ICER's expert group unanimously voted against Biogen's Aduhelm and its benefit for Alzheimer's patients. (Biogen) By Noah Higgins-Dunn |...

Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing...

Kimberly Grant, PharmD, and Julia Mahler, PharmD, clinical pharmacists with IPD Analytics, state that specialty products are outpacing...

Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar...

With multiple adalimumab biosimilars poised to enter the market and more biosimilars in more disease states seeking interchangeability,...

As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents. By Laura Joszt...

Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among...

In 2022 and 2023, there are a number of big therapies losing patent exclusivity, which opens the door to generics that could save as much...